Background: The prevalence of drug-induced parkinsonism (DIP) has been reported with the use of trimetazidine (TMZ), an antianginal medication available in Asian and European countries. Very few studies have evaluated the association between DIP and TMZ use, and studies using population-based data from national databases are lacking. Objectives: To investigate the association between DIP and use of TMZ in patients with angina using data from a national healthcare claims database and to determine the predictive factors of DIP in TMZ use. Methods: A cross-sectional study was conducted on patients aged 40 years or more diagnosed with angina, using the Korean National Healthcare claims 2014 database. The association between TMZ use and DIP was evaluated using multivariate logistic regression analysis, adjusting for confounders, including age; sex; insurance type; comorbidities; and concurrent medications known to be commonly associated with DIP, such as typical and atypical antipsychotics. Results: Of the patients included in the study, 19% were prescribed TMZ. In addition, 2.5% of TMZ users had preexisting extrapyramidal and movement disorders. TMZ use was found to be a significant predictor of a new diagnosis of parkinsonism (adjusted OR [aOR] 1.39; 95% CI 1.06–1.81; p = 0.016). Age ≥65 years (aOR 2.07; 95% CI 1.13– 3.74; p = 0.017) and stroke as comorbid disease (aOR 3.23; 95% CI 1.87–5.61; p < 0.001) were also significantly associated with a new diagnosis of parkinsonism in TMZ users. Conclusions: Treatment with TMZ was a statistically significant predictor of a new diagnosis of parkinsonism. Efforts should focus on close monitoring of, and education on, TMZ use in relation to DIP in all patients who are prescribed TMZ, including those with preexisting extrapyramidal and movement disorders.

1.
Dézsi CA. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.
Am J Ther
. 2016 May-Jun; 23(3):e871–9.
2.
Kyeong Hye J, Euni L. A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine.
Korean J Clin Pharm
. 2016; 26: 172–80.
3.
European Medicines Agency. Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution). EMA; 2012.
4.
Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.
Drugs
. 2014 Jun; 74(9): 971–80.
5.
López-Sendón J, Mena MA, de Yébenes JG. Drug-induced parkinsonism.
Expert Opin Drug Saf
. 2013 Jul; 12(4): 487–96.
6.
Shin HW, Chung SJ. Drug-induced parkinsonism.
J Clin Neurol
. 2012 Mar; 8(1): 15–21.
7.
Sethi KD. Movement disorders induced by dopamine blocking agents.
Semin Neurol
. 2001; 21(1): 59–68.
8.
Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced parkinsonism: a review.
Fundam Clin Pharmacol
. 1994; 8(4): 293–306.
9.
Martí Massó JF. [Trimetazidine-induced parkinsonism].
Neurologia
. 2004 Sep; 19(7): 392–5.
10.
Martí Massó JF, Martí I, Carrera N, Poza JJ, López de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor.
Therapie
. 2005 Jul-Aug; 60(4): 419–22.
11.
Masmoudi K, Masson H, Gras V, Andréjak M. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases.
Fundam Clin Pharmacol
. 2012 Apr; 26(2): 198–203.
12.
Kerlinger FN, Lee HB.
Foundations of behavioral research
. Fort Worth (TX): Harcourt College Publishers; 2000.
13.
Will JC, Loustalot F, Hong Y. National trends in visits to physician offices and outpatient clinics for angina 1995 to 2010.
Circ Cardiovasc Qual Outcomes
. 2014 Jan; 7(1): 110–7.
14.
Huang HC, Tsai CH, Muo CH, Lin KH, Lu MK, Sung FC, et al. Risk of Parkinson’s disease following zolpidem use: a retrospective, population-based cohort study.
J Clin Psychiatry
. 2015 Jan; 76(1):e104–10.
15.
Wang IK, Lin CL, Wu YY, Chou CY, Lin SY, Liu JH, et al. Increased risk of Parkinson’s disease in patients with end-stage renal disease: a retrospective cohort study.
Neuroepidemiology
. 2014; 42(4): 204–10.
16.
Ma HI, Kim JH, Chu MK, Oh MS, Yu KH, Kim J, et al. Diabetes mellitus and drug-induced Parkinsonism: a case-control study.
J Neurol Sci
. 2009 Sep; 284(1-2): 140–3.
17.
Lin HL, Lin HC, Tseng YF, Chen SC, Hsu CY. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.
Eur J Clin Pharmacol
. 2017 Mar; 73(3): 365–71.
18.
Ahn HJ, Yoo WK, Park J, Ma HI, Kim YJ. Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics.
J Korean Med Sci
. 2015 Sep; 30(9): 1328–33.
19.
Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples.
Epidemiol Health
. 2014 Jul; 36:e2014008.
20.
James AL, Thorp MA. Menière's disease.
BMJ Clin Evid
. 2007 Mar 1; 2007.
21.
Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
Mov Disord
. 2017 Feb; 32(2): 227–34.
22.
Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism.
Arch Intern Med
. 2005 Sep; 165(16): 1882–8.
23.
Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ. Levosulpiride-induced movement disorders.
Mov Disord
. 2009 Nov; 24(15): 2249–53.
24.
Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study.
J Cereb Blood Flow Metab
. 1995 May; 15(3): 513–8.
25.
Briani C, Cagnin A, Chierichetti F, Tiberio M, Battistin L, Pizzolato G. Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.
Eur J Neurol
. 2004 Oct; 11(10): 709–10.
26.
Barré J, Ledudal P, Oosterhuis B, Brakenhoff JP, Wilkens G, Sollie FA, et al. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure.
Biopharm Drug Dispos
. 2003 May; 24(4): 159–64.
27.
European Medicines Agency. Assessment Report for trimetazidine containing medicinal products. 2012; EMA.
28.
Korczyn AD. Vascular parkinsonism—characteristics, pathogenesis and treatment.
Nat Rev Neurol
. 2015 Jun; 11(6): 319–26.
29.
Becker C, Jick SS, Meier CR. Risk of stroke in patients with idiopathic Parkinson disease.
Parkinsonism Relat Disord
. 2010 Jan; 16(1): 31–5.
30.
Ministry of Food and Drug Safety.
Dear Healthcare Professional Letter
. Trimetazidine; 2012.
31.
Metazin (trimetazidine) [package insert]. Seoul: Daehan New Pharm Corp; 2014.
32.
Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France.
Mov Disord
. 2011 Oct; 26(12): 2226–31.
33.
Park B, Sung J, Park K, Seo S, Kim S.
Studying on diagnosis accuracy for health insurance claims data in Korea
. Seoul: Seoul National University; 2003. pp. 17–29.
34.
Kim J.
Strategies to enhance the use of National Health Insurance claims database in generating health statistics
. Seoul: Health Insurance Review and Assessment Services; 2005.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.